Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
The in vivo efficacy of vancomycin and teicoplanin against five Staphylococcus aureus strains with different susceptibilities to them and methicillin was studied. Rabbits were allocated at random to groups for endocarditis induction with one of these five strains and then treated for 2 days with vancomycin or teicoplanin. Each treated group was compared with a control group infected with the same strain. Vancomycin and teicoplanin showed similar activities. Low MICs did not predict better in vivo results.
Asseray
Nathalie
N
Laboratoire Antibiologie, UPRES EA 3826, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes, France.
Jacqueline
Cedric
C
Le Mabecque
Virginie
V
Batard
Eric
E
Bugnon
Denis
D
Potel
Gilles
G
Caillon
Jocelyne
J
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001011:Aorta / Q000382:microbiology; D015169:Colony Count, Microbial; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D006020:Glycopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D008712:Methicillin / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D017334:Teicoplanin / Q000494:pharmacology / Q000627:therapeutic use; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D010406:Penicillins; D017334:Teicoplanin; D014640:Vancomycin; D008712:Methicillin